No Data
No Data
Express News | ProMIS Neurosciences Inc Files for Resale From Time to Time of 56.5 Mln Common Shares of Co by Selling Stockholders - SEC Filing
Express News | ProMIS Neurosciences Granted US Patent 12,071,472 For "Methods Of Reducing Toxicity Induced By Amyloid Beta Oligomers Using Antibodies Specific To A-Beta Oligomers" In Alzheimer's Treatment
Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
ProMIS Neurosciences GAAP EPS of -$0.13
Buy Rating on ProMIS Neurosciences Backed by Innovative Alzheimer's Treatment and Strong Financials
Express News | ProMIS Neurosciences Q2 2024 GAAP EPS $(0.13) Beats $(0.14) Estimate
No Data